02297 潤邁德 - B
RAINMED-B
RAINMED-B
| Listing Date | 2022/07/08 |
| Listing Price | 6.240 |
Quote
Subscription Result
- Subscription Rate6.35x
- Guarantee One Lot Size15 lot
- One Lot Success Rate20.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Rainmed Medical Limited founded in 2014, it is a China-based medical device company, with focus on the design, development and commercialization of coronary angiography-derived fractional flow reserve system (caFFR System) and coronary angiography-derived index of microvascular resistance system (caIMR System).
Its Core Products, caFFR System and caIMR System, used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (“CAD”). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment.
Its caFFR System has obtained both certificates of CE Mark in Europe and NMPA approval in China. Building on its caFFR System and caIMR System, it aims to launch vascular interventional surgical robot, to automate the whole process of percutaneous coronary intervention (“PCI”) by 2024.
--
The Group had 81 approved patents, including 79 approved in China, one approved in the U.S. and one approved in Japan; 145 pending patent applications, including 106 in China and 39 overseas; 36 active PCT patent applications; 269 registered trademarks; and10 registered software copyrights. It also held six material patents and four material patent applications in relation to its caFFR System and four material patents and three material patent applications in relation to caIMR System.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 1000 |
GLOBAL OFFERING
| No. of Offer Shares | 23.35M shares |
| No. of International Offer Shares | 21.01M shares |
| No. of HK Offer Shares | 2.34M shares |
| Offer Price | $4.28 - $6.24 |
| Stock Code | 2297 |
| Sponsor(s) | Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | Huatai Financial Holdings (Hong Kong) Limited, Zhongtai International Securities Limited, BOCOM International Securities Limited, Eddid Securities and Futures Limited, Livermore Holdings Limited |
TIME TABLE
| Application Period | Jun 27 (Mon) - noon, Jun 30 (Thu) |
| Price Determination Date | Jun 30 (Thu) |
| Result Announcement Date | On or before Jul 07 (Thu) |
| Result Announcement Date | On or before Jul 07 (Thu) |
| Dealings in Shares commence on | Jul 08, 2022. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $4.28 - $6.24 |
| Capitalization | 5.00B - 7.28B |
| NAV / share ($) | $0.65 - $0.68 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 5.26, the net proceeds raised would be HKD 57.60M, of which |
| 80% : To fund the research and development as well as commercialization of Core Products caFFR System and caIMR System |
| 16.5% : To fund the ongoing research and development, manufacturing and commercialization of other pipeline products |
| 3.5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).